Clinical trials: Essential Hypertension.
Hypertension Essential, Salt Excess
Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant
The study is a non-pharmacological interventional, single-center, national, non-randomised, comparative and open label.
- Conditions
- Hypertension Essential, Salt Excess, Genetic Hypertension
- Trial name
- ADD-AMI (NCT06416735)
- Testing
- Amiloride
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Ospedale San Raffaele
Hypertension
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
The purpose of this study is to evaluate the safety and blood pressure lowering effect of different doses of PF-00489791 in patients with mild to moderate high blood pressure
- Trial name
- NCT00422461
- Testing
- PF-00489791
- Where
- 20 sites in United States
- Volunteers
- 135 people
- Sponsor
- Pfizer
Diabetes Mellitus, Essential Hypertension
Autonomic Imbalance and 24-h Blood Pressure Change in Patients With Chronic Renal Disease
Many patients with chronic renal disease show a loss of the nocturnal decline of blood pressure (non-dipper). However, the mechanism is not yet fully understood.
- Conditions
- Diabetes Mellitus, Essential Hypertension, Renal Failure, Chronic Nephropathy
- Trial name
- NCT00298129
- Testing
- Ambulatory blood pressure monitoring
- Where
- Japan
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Yokohama City University Medical Center
Hypertension
Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients
The purpose of this study is to evaluate of efficacy and safety of HCP1904-3 and RLD2001-1 alone in patients with essential hypertension inadequately controlled on RLD2001-1 monotherapy.
- Trial name
- NCT05199129
- Testing
- HCP1904-3, RLD2001-1
- Where
- South Korea
- Volunteers
- 166 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
Assessment of the long-term safety and tolerability of the combination of aliskiren and valsartan (300 mg/ 320 mg) in patients with high blood pressure,followed by assessment of long-term safety and tolerability of the…
- Trial name
- NCT00386607
- Testing
- Aliskiren, Valsartan, Hydrochlorothiazide (HCTZ)
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 601 people
- Sponsor
- Novartis
Essential Hypertension
Motivational Interviewing
The purpose of this project is to study ways to make it more likely that patients will take their blood pressure medicine as recommended by their doctors.
- Trial name
- NCT00208104
- Testing
- Motivational Interviewing
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- Columbia University
Essential Hypertension
Olmesartan as an add-on to Amlodipine in Hypertension
This study is to test the efficacy and safety of the combination of olmesartan and amlodipine in hypertensive patients whose blood pressure is not adequately controlled with amlodipine alone
- Trial name
- NCT00220233
- Testing
- olmesartan medoxomil, amlodipine, hydrochlorothiazide
- Where
- 5 sites in Germany
- Volunteers
- 632 people
- Sponsor
- Sankyo Pharma Gmbh
Hypertension
Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension
The purpose of this study is to evaluate the safety and tolerability of nebivolol and valsartan given as a free tablet combination in patient with stage 1 or stage 2 essential hypertension.
- Trial name
- NCT01415505
- Testing
- Nebivolol, Valsartan and Hydrochlorothiazide
- Where
- 135 sites in United States
- Volunteers
- 812 people
- Sponsor
- Forest Laboratories
Hypertension,Essential
Impact of Aerobic Exercise Training on Sympathetic Vasoconstriction and Vascular Function in Essential Hypertension
Sympathetic nervous activity plays an important role in the development of hypertension and studies have shown that the pannexin-1 channel is involved in the signalling of the sympathetic activity to the vascular bed.
- Trial name
- IMPROVEH (NCT03778489)
- Testing
- Training
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Uncomplicated Hypertension, Hypertension
The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients
The sustained reduction in elevated blood pressure and lower incidence of adverse events of Lacidipine may provide additional benefits for hypertension patients than other CCBs (calcium channel blockers).
- Conditions
- Uncomplicated Hypertension, Hypertension, Essential
- Trial name
- NCT00338338
- Testing
- Lacidipine 4 or 6 mg (oral), Amlodipine 5 or 10 mg(oral)
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Essential Hypertension
Evaluation of a Transmedial Psychoeducational Program to Improve Pharmacological Adherence
Population in Chile has experienced an accelerated process of demographic aging, which leads to changes in the composition of morbidity and mortality, with chronic noncommunicable diseases currently predominating.
- Trial name
- AFAM (NCT03924115)
- Testing
- Transmedial Psychoeducational Program to improve adherence full or partial (PS)
- Where
- Chile
- Volunteers
- 215 people
- Sponsor
- Universidad de Concepcion
Essential Hypertension
Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
The purpose of this study was to evaluate the dose-response relationships of azilsartan, once daily (QD) in participants with mild to moderate uncomplicated essential hypertension.
- Trial name
- NCT01289132
- Testing
- Azilsartan, Candesartan cilexetil
- Volunteers
- 926 people
- Sponsor
- Takeda
Essential Hypertension
Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets
The purpose of this study is to determine the optimal dosage of the clinical trial which is evaluating the antihypertensive efficacy and the safety of OJP-2028 tablets in patients with the uncomplicated essential hypertension.
- Trial name
- NCT00553865
- Testing
- OJP-2028
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Hypertension
A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan
- Trial name
- NCT01518998
- Where
- South Korea
- Volunteers
- 420 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Effects of Dark Chocolate on Insulin Sensitivity in People With High Blood Pressure
This study will examine whether dark chocolate affects the way patients with hypertension (high blood pressure) respond to insulin, a hormone secreted by the pancreas that regulates blood glucose (sugar) levels.
- Trial name
- NCT00099476
- Testing
- Effects of dark chocolate
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Hypertension, Quality of Life
Trans Cutaneous Electrical Acupoint Stimulation Versus TENS On Blood Pressure In Primary Hypertension Patients
To compare between the effects of transcutaneous electrical acupoint stimulation and TENS on blood pressure and quality of life in patients with primary hypertension BACKGROUND: The current American College of Cardiology and the…
- Trial name
- NCT06401278
- Testing
- Transcutaneous electrical acupoint stimulation, Transcutaneous electrical nerve stimulation (group b):
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tawfik Tawfik Mahmoud Emara
Essential Hypertension
Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)
An efficacy and safety study of hydrochlorothiazide (+) losartan potassium compared to amlodipine at week 12 in Korean patients with essential hypertension
- Trial name
- NCT00157963
- Testing
- MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks
- Volunteers
- 174 people
- Sponsor
- Organon and Co
Essential Hypertension
Helius in Hypertension-I: The UK Hypertension Registry
The purpose of this study is to demonstrate the use of a digital health offering in the management of persistent hypertension during chronic anti-hypertensive treatment.
- Trial name
- NCT02553512
- Testing
- Ingestible Sensor and Wearable Sensor
- Volunteers
- 151 people
- Sponsor
- Proteus Digital Health, Inc.
Essential Hypertension
Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy
CS-8635 combines three widely prescribed antihypertensive medications, olmesartan medoxomil(OM), amlodipine (AML), and hydrochlorothiazide (HCTZ), to lower blood pressure.
- Trial name
- NCT01838850
- Where
- 39 sites in South Korea
- Volunteers
- 344 people
- Sponsor
- Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company
Hypertension
Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension
To evaluate the trough and peak effect of once daily MICARDIS PLUS (Telmisartan 80 mg/hydrochlorothiazide 12.5 mg) by 24 ABPM in patients with mild to moderate essential hypertension.
- Trial name
- NCT00257491
- Testing
- Telmisartan, Telmisartan/HCTZ
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim